DelMar Pharmaceuticals Inc (NASDAQ:DMPI) shares shot up 6.5% during mid-day trading on Wednesday . The company traded as high as $0.66 and last traded at $0.66, 350,500 shares traded hands during trading. A decline of 6% from the average session volume of 374,793 shares. The stock had previously closed at $0.62.
A number of research firms recently issued reports on DMPI. Dawson James reissued a “buy” rating on shares of DelMar Pharmaceuticals in a research report on Thursday, July 11th. ValuEngine cut DelMar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 2nd. Finally, Maxim Group began coverage on DelMar Pharmaceuticals in a research report on Friday, September 6th. They set a “buy” rating for the company.
The stock has a market cap of $1.69 million, a price-to-earnings ratio of -0.22 and a beta of 1.13. The business has a 50-day moving average of $1.08 and a 200-day moving average of $1.13.
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.
Recommended Story: Stock Symbol
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.